Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.06)
# 617
Out of 4,906 analysts
44
Total ratings
54.55%
Success rate
13.02%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $4.54 | +142.29% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $1.88 | +59.57% | 1 | Jul 1, 2025 | |
| INDV Indivior | Maintains: Buy | $15 → $22 | $15.60 | +41.03% | 4 | Jun 30, 2025 | |
| NRXS NeurAxis | Initiates: Buy | $7 | $2.73 | +156.41% | 1 | Jun 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $7.83 | +117.11% | 3 | Jun 9, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $12 → $13 | $8.40 | +54.76% | 5 | May 14, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $14.40 | +94.44% | 6 | May 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $5 → $6.5 | $5.14 | +26.46% | 1 | Mar 7, 2025 | |
| MDWD MediWound | Initiates: Buy | $39 | $20.07 | +94.32% | 1 | Feb 28, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Buy | $10 → $8 | $0.76 | +947.94% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $11.32 | +85.51% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $3.46 | +73.41% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $12 | $5.13 | +133.92% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.75 | +166.67% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $65 | $37.08 | +75.30% | 3 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $6.65 | +80.45% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $8.50 | +17.65% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $10.98 | +109.47% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.62 | +93.55% | 2 | Jul 11, 2023 |
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $4.54
Upside: +142.29%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $1.88
Upside: +59.57%
Indivior
Jun 30, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $15.60
Upside: +41.03%
NeurAxis
Jun 16, 2025
Initiates: Buy
Price Target: $7
Current: $2.73
Upside: +156.41%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $7.83
Upside: +117.11%
Fennec Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $8.40
Upside: +54.76%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $14.40
Upside: +94.44%
Xeris Biopharma Holdings
Mar 7, 2025
Maintains: Buy
Price Target: $5 → $6.5
Current: $5.14
Upside: +26.46%
MediWound
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $20.07
Upside: +94.32%
Ironwood Pharmaceuticals
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $0.76
Upside: +947.94%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $11.32
Upside: +85.51%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $3.46
Upside: +73.41%
Nov 14, 2024
Maintains: Buy
Price Target: $16 → $12
Current: $5.13
Upside: +133.92%
Nov 4, 2024
Initiates: Buy
Price Target: $10
Current: $3.75
Upside: +166.67%
Oct 4, 2024
Maintains: Buy
Price Target: $45 → $65
Current: $37.08
Upside: +75.30%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $6.65
Upside: +80.45%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $8.50
Upside: +17.65%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $10.98
Upside: +109.47%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.62
Upside: +93.55%